Trial Profile

A phase I/II clinical trial of ICTCAR014 in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), including patients whose tumors are PD-L1 positive.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 09 Dec 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Dec 2019 According to an Innovative Cellular Therapeutics media release, this trial is expected to begin in the first part of 2020. Dr. David L. Porter of the Abramson Cancer Center of the University of Pennsylvania will be the Lead Principal Investigator for the clinical trial.
04 Dec 2019 According to an Innovative Cellular Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ICTCAR014.
19 Mar 2019 According to an Innovative Cellular Therapeutics media release, company has received positive feedback from the U.S. Food and Drug Administration during the pre-IND meeting and plan to submit an IND for ICTCAR014 to the FDA in the second quarter of 2019

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com